Research programme: bacteriophage therapeutics - Ferring Pharmaceuticals/Institut Pasteur

Drug Profile

Research programme: bacteriophage therapeutics - Ferring Pharmaceuticals/Institut Pasteur

Latest Information Update: 19 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ferring Pharmaceuticals; Institute Pasteur
  • Developer Ferring Pharmaceuticals; Institute Pasteur; Intralytix
  • Class Bacteriophages
  • Mechanism of Action Bacterial DNA modulators; Bacterial RNA modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Inflammatory bowel diseases
  • Research Bacterial infections

Most Recent Events

  • 15 Feb 2018 Preclinical trials in Inflammatory bowel disease in Switzerland (unspecified route)
  • 15 Feb 2018 US FDA approves IND application for bacteriophage formulation in Crohn's disease
  • 15 Feb 2018 Intralytix plans a phase I/IIa trial for Crohn's disease in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top